Heparin induced thrombocytopenia: review

被引：8

作者：

Dasararaju, Radhika ^{[1
]}

Singh, Nirupama ^{[1
]}

Mehta, Amitkumar ^{[2
]}

机构：

[1] Univ Alabama Birmingham, Dept Transfus Med, Birmingham, AL 35249 USA

[2] Univ Alabama Birmingham, Dept Hematol & Oncol, Birmingham, AL 35294 USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2013年 / 6卷 / 04期

关键词：

argatroban; danaparoid; desirudin; fondaparinux; heparin; heparin-induced thrombocytopenia; HIT; lepirudin; thrombocytopenia; 4T score; MOLECULAR-WEIGHT HEPARIN; RECOMBINANT HIRUDIN; TISSUE FACTOR; ANTIBODIES; THROMBOSIS; RISK; PLATELET-FACTOR-4; DIAGNOSIS; LEPIRUDIN; HIT;

D O I：

10.1586/17474086.2013.814446

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heparin induced thrombocytopenia (HIT) is a serious, potentially life and limb threatening immune adverse reaction to heparin. IgG antibodies against platelet factor 4 and heparin multimer complexes activate platelets to create a prothrombotic state. ELISA based immunoassay to detect these antibodies is sensitive while serotonin release assay is highly specific but is not widely available. 4T score is a simple score to calculate pre-test probability of HIT. Score <3 is highly specific to exclude the diagnosis. Alternate anticoagulants like lepirudin, argatroban or danaparoid are recommended in therapeutic dose to treat or prevent thrombotic events in HIT. Increased awareness of this condition among clinicians is important to ensure its early recognition and treatment to avoid serious complications.

引用

页码：419 / 428

页数：10

共 78 条

[71] The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia [J].

Warkentin, TE ;

Elavathil, LJ ;

Hayward, CPM ;

Johnston, MA ;

Russett, JI ;

Kelton, JG .

ANNALS OF INTERNAL MEDICINE, 1997, 127 (09) :804-+

[72] A 14-year study of heparin-induced thrombocytopenia [J].

Warkentin, TE ;

Kelton, JG .

AMERICAN JOURNAL OF MEDICINE, 1996, 101 (05) :502-507

[73]

Warkentin Theodore E, 2003, Hematology Am Soc Hematol Educ Program, P497

[74] Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia [J].

Warkentin, Theodore E. ;

Sheppard, Jo-Ann I. ;

Sigouin, Christopher S. ;

KohImann, Thomas ;

Eichler, Petra ;

Greinacher, Andreas .

BLOOD, 2006, 108 (09) :2937-2941

[75] HITlights: A career perspective on heparin-induced thrombocytopenia [J].

Warkentin, Theodore E. .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 :S92-S99

[76] Heparin-Induced Thrombocytopenia in Critically III Patients [J].

Warkentin, Theodore E. .

CRITICAL CARE CLINICS, 2011, 27 (04) :805-+

[77]

Warkentin TE, 2010, EXPERT REV HEMATOL, V3, P567, DOI [10.1586/ehm.10.54, 10.1586/EHM.10.54]

[78] Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia [J].

Ziporen, L ;

Li, ZQ ;

Park, KS ;

Sabnekar, P ;

Liu, WY ;

Arepally, G ;

Shoenfeld, Y ;

Kieber-Emmons, T ;

Cines, DB ;

Poncz, M .

BLOOD, 1998, 92 (09) :3250-3259

← 1 2 3 4 5 6 7 8 →